Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Systematic analysis of gene mutations in Chinese multiple myeloma patients.

Jinhua Wang, Hongxiao Han, Qun Li, Chi Ma, Hao Cai, Linyu Cai, Kaini Shen, Fei Zhao, Jian Xu, Lu Zhang, Bo Zhang, Jian Li, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3989.

https://doi.org/10.1182/blood-2025-3989

Published: 2025

Journal Articles

Single-cell landscape of clonal plasma cells in t(11;14) primary light-chain amyloidosis reveals molecular insights into venetoclax response

Xinyi Xiong, Xuezhu Wang, Hong-Xiao Han, Ai Guan, Kaini Shen, Jian Li

Blood (2025) 146 (Supplement 1): 3971.

https://doi.org/10.1182/blood-2025-3971

Published: 2025

Journal Articles

Long-term follow-up of a prospective phase 2 Study of daratumumab plus bortezomib and dexamethasone in newly diagnosed mayo 2004 stage IIIA and IIIb light-chain amyloidosis

Xuemin Gao, Kaini Shen, Yajuan Gao, Ai Guan, Yi Xu, Long Chang, Jian Li

Blood (2025) 146 (Supplement 1): 3965.

https://doi.org/10.1182/blood-2025-3965

Published: 2025

Journal Articles

Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab

Yi Xu, Chengyang Xu, Ai Guan, Kaini Shen, Jian Li

Blood (2025) 146 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2025-2190

Published: 2025

Journal Articles

Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study

Kaini Shen, Liye Zhong, Peilong Lai, Chunyan Sun, Donghua He, Ai Guan, Yi Xu, Jian Li

Blood (2025) 146 (Supplement 1): 7492.

https://doi.org/10.1182/blood-2025-7492

Published: 2025

Journal Articles

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Chong Wei, Wei Zhang, Dao-Bin Zhou, Jian Li, Yan Zhang, Kaini Shen, Wei Wang, Zi Wang, Danqing Zhao, Jing Ruan, Huacong Cai, Yueying Mao

Blood (2025) 146 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2025-6322

Published: 2025

Journal Articles

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

Jian Xu, Jian Li, Yongqiang Wei, Weijun Fu, Bingzong Li, Xiu Li Sun, Kaini Shen, Xiaolei Wei, Lu Li, Liying Zhang, He Xu, Yueying Mao, Dehu Li, Aoshuang Xu, Fei Zhao, Chunyan Sun

Blood (2025) 146 (Supplement 1): 5828.

https://doi.org/10.1182/blood-2025-5828

Published: 2025

Journal Articles

Single–cell analysis of BCR and transcriptome uncovers plasma cell clonal dynamics and immune exhaustion linked to daratumumab response in primary light–chain amyloidosis

Xuezhu Wang, Xinyi Xiong, Hong-Xiao Han, Ai Guan, Kaini Shen, Jian Li

Blood (2025) 146 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2025-2158

Published: 2025

Journal Articles

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis

Xinyi Xiong, Ai Guan, Yi Xu, Chengyang Xu, Kaini Shen, Jian Li

Blood (2025) 146 (Supplement 1): 5745.

https://doi.org/10.1182/blood-2025-5745

Published: 2025

Journal Articles

Real-World Data of Siltuximab for Chinese Patients with Imcd: Combination with BCD Regimen Benefits Severe Cases

Siyuan Li, Yuhan Gao, Yue Dang, Long Chang, Kaini Shen, Huacong Cai, Danqing Zhao, Chong Wei, Jun Feng, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6292.

https://doi.org/10.1182/blood-2024-203586

Published: 2024

Journal Articles

Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Kaini Shen, Ai Guan, Yu Wu, Chunyan Sun, Liye Zhong, Jun Luo, Jian Li

Blood (2024) 144 (Supplement 1): 893.

https://doi.org/10.1182/blood-2024-204346

Published: 2024

Journal Articles

The De Novo Sequencing of Full-Length Amyloidogenic Light Chain By Peripheral Blood Mass Spectrometry

Ai Guan, Kaini Shen, Wei Su, Bing Wang, Bin Ma, Jian Li

Blood (2024) 144 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2024-204407

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study

Ya-Juan Gao, Kaini Shen, Long Chang, Jun Feng, Yueying Mao, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li

Blood (2022) 140 (Supplement 1): 4391–4392.

https://doi.org/10.1182/blood-2022-157044

Published: 2022

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis

Kaini Shen, Congli Zhang, Jun Feng, MD, Lu Zhang, Xinxin Cao, Daobin Zhou, MD, Jian Li, MD

Blood (2018) 132 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2018-99-112407

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Systematic analysis of gene mutations in Chinese multiple myeloma patients.

Single-cell landscape of clonal plasma cells in t(11;14) primary light-chain amyloidosis reveals molecular insights into venetoclax response

Long-term follow-up of a prospective phase 2 Study of daratumumab plus bortezomib and dexamethasone in newly diagnosed mayo 2004 stage IIIA and IIIb light-chain amyloidosis

Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab

Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

Single–cell analysis of BCR and transcriptome uncovers plasma cell clonal dynamics and immune exhaustion linked to daratumumab response in primary light–chain amyloidosis

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis

Real-World Data of Siltuximab for Chinese Patients with Imcd: Combination with BCD Regimen Benefits Severe Cases

Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

The De Novo Sequencing of Full-Length Amyloidogenic Light Chain By Peripheral Blood Mass Spectrometry

Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only